Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

The latest announcement is out from Alkermes ( ($ALKS) ). On January 6, 2026, Alkermes announced that the U.S. Food and Drug Administration ...

Alixorexton is an oral selective orexin 2 receptor agonist expected to reduce excessive daytime sleepiness across hypersomnolence disorders such as narcolepsy.

HOUSTON -- An investigational oral drug targeting the lack of brain orexin neuropeptides that characterizes narcolepsy type 1 demonstrated safety and effectiveness for the condition in a phase IIb ...

Jay Cook, 24, was in high school when she started to experience sudden bouts of sleepiness. "I was taking community college classes, and I'd drive 20 minutes away to the community college and come ...

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, and oral orexin 2 receptor agonist (formerly ALKS 2680), for the treatment ...

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. Matthew Horsnell began ...

"Our findings show that the schizophrenia diagnosis in narcoleptic patients is a phenomenon that does not occur only by chance but also having NT1 can be considered as a risk factor for developing ...